Serological survey and risk factors associated with Toxoplasma gondii infection among HIV-infected pregnant women attending Abuja Tertiary Hospital, Nigeria by Zakari, Maryam
Malawi Medical Journal 32 (3); 169-176 September 2020 Serological survey and risk factors associated with Toxoplasma gondii  160
Https://dx.doi.org/10.4314/mmj.v32i3.9 
© 2020 The College of  Medicine and the Medical Association of  Malawi. This work is licensed under the Creative Commons Attribution 4.0 International License.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Maryam Muhammad Zakari1, Aliyu Yabagi Isah1, Richard Offiong1, Thairu Yunusa2, Idris Nasir 
Abdullahi3
1. Department of  Obstetrics and Gynecology, University of  Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria
2. Department of  Medical Microbiology and Parasitology, University of  Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria
3. Department of  Medical Laboratory Science, Faculty of  Allied Health Sciences, Ahmadu Bello University, Zaria, Nigeria
Correspondence: Idris Nasir Abdullahi (inabdullahi@abu.edu.ng, eedris888@yahoo.com)
Serological survey and risk factors associated with 
Toxoplasma gondii infection among HIV-infected 





Toxoplasmosis in pregnancy could induce miscarriage, congenital anomalies in foetuses and encephalitis in HIV-infected people. 
Hence, there is a need to determine the prevalence of  toxoplasmosis in HIV-infected pregnant women to inform clinicians about the 
significance of  maternal toxoplasmosis in antenatal care.
Aim
This study aimed to determine the seroprevalence of  Toxoplasma gondii infection, associated CD4+ T-cell profile and sociodemographic 
risk factors among pregnant women with or without HIV infection attending the University of  Abuja Teaching Hospital, Abuja, 
Nigeria. 
Methods
This hospital-based cross-sectional study involved blood samples collected from 160 HIV-infected and 160 HIV-seronegative pregnant 
women. These samples were analysed for anti-T. gondii (IgG and IgM) and CD4+ T-cell count using ELISA and flow cytometry, 
respectively. Sociodemographic variables of  participants were collected using structured questionnaires. 
Results
The overall seroprevalence of  anti-T. gondii IgG and IgM was 28.8% and 3.8%, respectively. The seroprevalence of  anti-T. gondii IgG 
and IgM was 29.4% and 4.4%, respectively, among HIV-seropositive pregnant women and 28.1% and 3.1%, respectively, among HIV-
seronegative women. There was no significant association between the seroprevalence of  anti-T. gondii-IgG and anti-T. gondii-IgM 
with age, gestational age, education level, parity or place of  residence of  HIV-infected pregnant women (P > 0.05). However, there was 
significant association between the seroprevalence of  anti-T. gondii-IgG (P = 0.03) and anti-T. gondii-IgM (P = 0.01) with education 
level. CD4+ T-cell count varied significantly between HIV-infected and HIV-uninfected pregnant women (P = 0.035). 
Conclusion 
In this study, the seroprevalence of  anti-T. gondii IgG and IgM did not differ in HIV-seropositive or HIV-seronegative pregnant 
women. However, women with primary T. gondii and HIV coinfection had lower CD4+ T-cell count than those with toxoplasmosis 
monoinfection. 
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Introduction
Toxoplasma gondii, the aetiological agent of  toxoplasmosis, 
is a zoonotic parasite that has latently affected 33.8% of  
pregnant women worldwide in the last three decades1. The 
ubiquitous obligate intracellular coccidian protozoan infects 
a wide variety of  domesticated animals (such as cats and 
dogs), birds and humans1. Clinically, toxoplasmosis is an 
opportunistic parasitic infection in immunocompromised 
and immunosuppressed people that has led to serious public 
health morbidities including physical and/or psychological 
sequelae for people living with HIV/AIDS2. However, in 
the vast majority of  immunocompetent people, T. gondii 
infection is latent, characterised by the persistence of  the 
parasites in the brain, skeletal muscles and heart without 
causing clinical diseases3.
In chronically infected people who develop cell-mediated 
immunodeficiency, symptomatic toxoplasmosis is more 
likely to occur as a result of  reactivated infection, especially 
due to CD4+ T lymphopenia4 below 100 cells/mm3. 
Consequently, toxoplasmosis among people living with 
HIV/AIDS mainly manifests as toxoplasma encephalitis5. 
In pregnant women, toxoplasmosis has been implicated in 
prenatal and congenital transmission, causing miscarriage 
or congenitally acquired disorders that primarily affect the 
central nervous system of  neonates6. Nigeria has one of  
the highest HIV prevalences, with 1.4% among adults aged 
15–49 years in 2019. HIV prevalence was highest among 
females aged between 35 and 39 years7. According to the 
recent Nigeria National AIDS Indicator Survey, Abuja 
was 15th out of  37 states and the capital for highest HIV 
prevalence. People living in the Abuja suburbs had relatively 
higher rates of  HIV infection compared with those residing 
in the main Abuja city. Furthermore, higher prevalence was 
reported among women within the reproductive age group7. 
An overall toxoplasmosis prevalence of  31.5% was reported 
in Abuja8 with similar immunoglobulin M and G (IgM and 
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IgG) seropositivity, as previously reported in other Nigerian 
studies9,10.  When a pregnant woman contracts T. gondii 
infection in the first trimester which is allowed to be untreated, 
the risk of  miscarriage is significantly high11. However, in the 
third trimester, untreated T. gondii infection increases the risk 
of  toxoplasma-induced congenital anomalies in neonates11.
There is a paucity of  studies in Nigeria that focus on 
simultaneous investigation of  toxoplasmosis and its impact 
of  CD4+ T cellular immunity in pregnant women living 
with HIV/AIDS in comparison to those who are HIV 
seronegative. Hence, this study sought to determine the 
seroprevalence of  anti-T. gondii, associated CD4+ T-cell 
profile and sociodemographic risk factors among pregnant 
women with or without HIV infection attending the 
University of  Abuja Teaching Hospital (UATH) in Nigeria.
Methods
Study design
This was a hospital-based cross-sectional study.
Study area
This study was conducted between 2 February 2017 and 
28 January 2018 at the Department of  Obstetrics and 
Gynecology and Immunology, UATH, Abuja. The hospital 
provides healthcare services to the inhabitants of  Abuja 
and neighbouring states including Niger, Kaduna, Kogi 
and Nasarawa states. The hospital has an average of  3000 
deliveries annually. The laboratory investigations were carried 
out at the Immunology Laboratory of  UATH.
Study population 
This included consecutively enrolled 160 HIV-seropositive 
and 160 HIV-seronegative pregnant women who attended 
antenatal clinics at UATH. All participants were retested 
for HIV serostatus using the World Health Organization 
(WHO) algorithm by Uni-Gold Recombigen HIV-1/2 
(Trinity Biotech, Wicklow, Ireland) and Determine™ (Alere, 
Auckland, New Zealand) proprietary reagents. There were 
no new HIV-seropositive cases and all the seropositive 
subjects were on antiretroviral therapy.
Sample size determination
The minimum sample size for this study was determined from 
the prevalence of  29.1% anti-toxoplasma IgG in pregnant 
women9 as 317. In total, 320 consenting participants were 
recruited.
Ethical considerations
The ethical approval for this study was obtained from the 
Research Ethics Committee of  the University of  Abuja 
Teaching Hospital (Approval Number: FCT/UATH/
HREC/PR/416). Written informed consent was sought 
from all participants before enrolment into the study. For 
participants who were not literate and those who may not 
have understood the medium of  communicating the study, 
translation was done using their local dialects before they 
consented by nodding their heads, signing the consent form 
or making a thumb-print on the signature area. All data 
were treated with utmost confidentiality. The protocols of  
this study were conducted in accordance with the Helsinki 
declaration of  1973 (revised in 2000)12.
Sample collection and processing
The purpose of  this work was explained to the subjects 
before their consent to participate was sought. Interviewer-
administered, structured questionnaires were used as a 
study tool. The questions outlined in the data forms were 
explained to the subjects and then completed with the 
required information which included bio-demographic data. 
Five millilitres of  blood was aseptically collected from each 
participant via venepuncture.
Three millilitres were dispensed into a plain (no-anticoagulant) 
container, while the remaining 2 ml was dispensed into an 
EDTA anticoagulated bottle which was used for CD4+ 
T-cell counts (within 1 h of  collection). The blood in the 
plain container was allowed to clot and retracted. The 
serum was harvested after separation from the red cells by 
centrifugation at 10,000 g for 10 min. The serum samples 
were appropriately labelled and refrigerated (2–8 °C) until 
ELISA analysis was done within 24 h of  collection.
Laboratory analysis 
Toxoplasma gondii IgG and IgM ELISA 
The samples were analysed for the presence of  IgG/IgM 
class antibodies to T. gondii by ELISA using Toxo IgG/Toxo 
IgM ELISA kits (Fortress Diagnostics Limited, Antrim, UK) 
which are qualitative and quantitative immunoassays for the 
detection of  human antibodies in serum or plasma directed 
against T. gondii. The interpretation of  tests and results was 
carried out based on the manufacturer’s instructions. 
Flow cytometry of CD4+ T lymphocytes
Based on the manufacturer’s instructions, the CD4+ cell 
counts in the whole blood were analysed using a Partec™ 
CyFlow Analyzer (Sysmex, Norderstedt, Germany) Model 
SL3. This device uses the principle of  light scattering (based 
on dissimilarity in cell size or granularity) and the fluorescence 
of  cells following staining with monoclonal antibodies 
to markers on the cell surface bound to fluorescent dyes. 
Flow cytometry data were analysed using FlowJo version 
7.6.5 software (Becton Dickinson, Franklin Lakes, NJ, 
USA) and cell populations of  interest were then gated after 
identification. The generated percentages were multiplied 
by the total number of  lymphocytes in the haemogram to 
derive absolute values for circulating lymphocytes. Absolute 
CD4+ cell counts were subsequently analysed using a single-
platform technique. 
Statistical analysis
The data were analysed using Statistical Package for Social 
Sciences (SPSS) software version 20.0 (IBM, CA, USA). Chi-
square was used to determine significant association between 
the prevalence of  anti-T. gondii and sociodemographic 
variables of  participants. The t-test was used to determine 
the difference between CD4+ T-cell counts between the two 
groups of  participants. One-way ANOVA with Tukey’s test 
was used to determine differences in CD4+ T-cell count 
across the three gestational groups of  subjects with HIV/T. 
gondii coinfection and T. gondii monoinfection. P-values 
≤0.05 at confidence interval (CI) of  95% were considered 
significant.
Results
The overall seroprevalence of  anti-T. gondii IgG and 
IgM was 28.8% and 3.8%, respectively. Of  the 160 HIV-
seropositive and 160 HIV-seronegative pregnant women 
tested, the seroprevalence of  anti-toxoplasma IgG and IgM 
was 29.4% and 4.4%, respectively, among HIV-seropositive 
pregnant women and 28.1% and 3.1%, respectively, among 
HIV-seronegative women (Table 1).The seroprevalence of  
anti-T. gondii IgG and IgM among HIV-seropositive pregnant 
women was highest among those aged 20–39 years, with 45 
(95.7%) and 7 (100.0%) seropositive cases, respectively, of  
IgG and IgM.
Those living in urban areas had more cases of  anti-T. gondii 
IgG and IgM antibodies than their rural counterparts (91.5% 
and 4% versus 100.0% and 0.0%, respectively) (Table 2). The 
seroprevalence of  anti-T. gondii IgG and IgM was highest 
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among HIV-seropositive pregnant women with tertiary 
education (20 [42.6%] and 5 [71.4%], respectively). Pregnant 
women at their third trimester (23 [48.9%] and 3 [42.9%]) 
had the highest prevalence of  anti-T. gondii IgG and IgM 
than those at their first and second trimester (19.2% versus 
14.2% and 31.9% versus 42.9%, respectively).
Table 1. Seroprevalence of Toxoplasma gondii antibodies among 
pregnant women (n = 320)
HIV-uninfected pregnant women with parity of  1–4 had 
the highest anti-T. gondii IgG (62.2%) when compared with 
the nulliparous (22.2%) and those with parity ≥5 (15.6%). 
Similarly, HIV-uninfected pregnant women with parity 
of  1–4 had the highest anti-T. gondii IgM (60.0%) when 
compared with the nulliparous (20.0%) and those with parity 
≥5 (20.0%) (Table 2). There was no significant association 
between the seroprevalence of  anti-T. gondii-IgG and -IgM 
with age, gestational age, educational level, parity and place 
of  residence of  HIV-infected pregnant women (P > 0.005) 
(Table 2).
The seroprevalence of  anti-T. gondii IgG and IgM was 
highest among HIV-seronegative pregnant women between 
20 and 39 years (40 [88.9%] and 5 [100.0%], respectively). 
Those living in urban areas had more cases of  anti-T. gondii 
IgG antibodies than their rural counterparts (84.4% versus 
80.0%) (Table 3). In contrast, the seroprevalence of  anti-T. 
gondii IgM was relatively lower among those residing within 
urban areas compared with rural residents (15.6% versus 
20.0%) (Table 3). 
The seroprevalence of  anti-T. gondii IgG and IgM was 
highest among HIV-seronegative pregnant women with 
tertiary education (33 [73.3%] and 5 [100.0%], respectively). 
Pregnant women at their third trimester had a higher 
prevalence of  anti-T. gondii IgG and IgM (23 [51.1%] and 
3 [60.0%], respectively) than those at their first and second 
trimester (13.3% versus 35.6% and 20.0% versus 20.0%, 
respectively).
Nulliparous HIV-infected pregnant women had the least 
anti-T. gondii IgG (12.8%) when compared with those with 
parity of  1–4 (46.8%) and ≥5 parity (40.4%). However, 
HIV-infected pregnant women with parity of  1–4 had the 
highest anti-T. gondii IgM (57.1%) when compared with 
the nulliparous (14.3%) and those with parity ≥5 (28.6%) 
(Table 3). There was significant association between the 
seroprevalence of  anti-T. gondii-IgG and -IgM with education 
level but only anti-T. gondii-IgM was significantly associated 
with place of  residence (P = 0.01). However, there was no 
association between age and parity of  HIV-seronegative 
pregnant women (P > 0.05) (Table 3).
HIV-infected pregnant women without anti-T. gondii IgM 












45 (28.1) 5 (3.1)
Total 92 (28.8) 12 (3.8)
*Significant difference determined by chi-square test.
Variable IgG IgM
Positive (%) Negative (%) P-value Positive (%) Negative (%) P-value
Age (years)
≤19 0 (0.0) 0 (0.0) 5 (3.3) 5 (4.4)
20–39 45 (95.7) 98 (86.7) 0.778 7 (100.0) 136 (88.9) 0.804
≥40 2 (4.3) 10 (8.9) 0 (0.0) 12 (7.8)
Place of residence
Urban 43 (91.5) 84 (74.3) 0.360 7 (100.0) 120 (78.4) 0.790




3 (6.4) 25 (22.1) 0 (0.0) 28 (18.3)
Primary 14 (29.8) 9 (8.0) 0.061 2 (28.6) 21 (13.7) 0.248
Secondary 10 (21.3) 38 (33.6) 0 (0.0) 48 (31.4)
Tertiary 20 (42.6) 41 (36.3) 5 (71.4) 56 (36.6)
Parity
Nulliparous 6 (12.8) 50 (44.3) 1 (14.3) 55 (35.9)
Parity 1–4 22 (46.8) 32 (28.3) 0.642 4 (57.1) 50 (32.7) 0.919
Parity ≥5 19 (40.4) 31 (27.4) 2 (28.6) 48 (31.4)
Gestational age
1st trimester 9 (19.2) 25 (22.1) 1 (14.2) 33 (21.6)
2nd trimester 15 (31.9) 38 (33.6) 0.606 3 (42.9) 50 (32.7) 0.119
3rd trimester 23 (48.9) 50 (44.3) 3 (42.9) 70 (45.7)
Table 2. Seroprevalence of anti-Toxoplasma gondii IgG and IgM by sociodemographic variables of HIV-infected pregnant women
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based on their T. gondii IgM serostatus, it was observed that 
HIV-infected pregnant women at their first trimester had 
the lowest mean CD4+ T-cell count (399±0 cells/mm3), 
followed by those in their third trimester (411±38.5 cells/
mm3), then those in their second trimester (523±41.3 cells/
mm3). There was significant difference in the mean CD4+ 
T-cell count of  HIV-seropositive pregnant women based on 
the three gestational groups and T. gondii IgM (P = 0.0048) 
and IgG status (P < 0.001) (Table 5). Based on the T. gondii 
IgG serostatus, it was observed that HIV-seronegative 
pregnant women at their first trimester had the lowest mean 
CD4+ T-cell count (562±67.2 cells/mm3), followed by those 
Table 3. Seroprevalence of anti-Toxoplasma gondii IgG and IgM by sociodemographic variables of HIV-seronegative pregnant women.
Variable IgG P-value IgM P-value
Positive (%) Negative (%) Positive (%) Negative (%)
Age (years)
≤19 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.6)
20–39 40 (88.9) 111 (96.5) 0.333 5 (100.0) 146 (94.2) 0.554
≥40 5 (11.1) 3 (2.6) 0 (0.0) 8 (5.2)
Place of resi-
dence
Urban 38 (84.4) 114 (99.1) 4 (80.0) 148 (95.5)





0 (0.0) 7 (6.1) 0 (0.0) 7 (4.5)
Primary 4 (8.9( 30 (26.1) 0.033 0 (0.0) 34 (22.0) 0.010
Secondary 8 (17.8) 50 (43.5) 0 (0.0) 58 (37.4)
Tertiary 33 (73.3) 28 (24.3) 5 (100.0) 56 (36.1)
Total 45 (100.0) 115 (100.0) 5 (100.0) 155 (100.0)
Parity
Nulliparous 10 (22.2) 9 (7.8) 1 (20.0) 18 (11.6)
Parity 1–4 28 (62.2) 56 (48.7) 0.125 3 (60.0) 81 (52.3) 0.073
Parity ≥5 7 (15.6) 50 (43.5) 1 (20.0) 56 (36.1)
Gestational age
1st trimester 6 (13.3) 20 (17.4) 1 (20.0) 25 (16.1)
2nd trimester 16 (35.6) 44 (38.3) 0.544 1 (20.0) 59 (38.1) 0.999
3rd trimester 23 (51.1) 51 (44.3) 3 (60.0) 71 (45.8)
*Significant difference determined by chi-square test
Table 4. Toxoplasma gondii serological status and CD4+ T-cell counts among HIV-infected pregnant women.
Sero-status Subjects (n) Mean±SD CD4+ P-value
(a) HIV+ and  
Toxo IgM+
7 324±23.4
(b) HIV+ and 
Toxo IgM−
153 431±55.1
Total 160 420±52.2 0.035
(a) HIV+ and 
Toxo IgG+
47 340±31.9
(b) HIV+ and IgG− 113 372±45.2
Total 160 330±33.5 0.075
*Significant difference determined by t-test
had significantly higher CD4+ T-cell count (431±55.1 cells/
mm3, mean±SD) than those who were anti-T. gondii IgM 
seropositive (324±23.4 cells/mm3; P = 0.035). However, 
HIV-infected pregnant women without anti-T. gondii IgG 
did not have a significantly different T-cell count (372±45.2 
cells/mm3) compared with those who were anti-T. gondii IgG 
seropositive (340±31.9 cells/mm3; P = 0.075) (Table 4).Based 
on T. gondii IgG serostatus, it was observed that HIV-infected 
pregnant women at their third trimester had the lowest mean 
CD4+ T-cell count (284±18.9 cells/mm3), followed by those 
in their second trimester (323±24.2 cells/mm3), then those 
in their first trimester (358±28.6 cells/mm3). However, 
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in their third trimester (582±68.1 cells/mm3), then those 
in their second trimester (611±72.9 cells/mm3). However, 
based on their T. gondii IgM serostatus, it was observed that 
HIV-seronegative pregnant women at their first trimester 
had the lowest mean CD4+ T-cell count (426±0 cells/mm3), 
followed by those in their second trimester (541±51.7 cells/
mm3), then those in their third trimester (598±72.5 cells/
mm3). There was no significant difference in the mean CD4+ 
T-cell count of  HIV-seronegative pregnant women based on 
the three gestation groups and T. gondii IgG (P = 0.27) and 
IgM status (P = 0.32) (Table 6). 
Discussion
In this study, the overall seroprevalence of  anti-T. gondii 
(both IgG and IgM) among HIV-positive and HIV-negative 
pregnant women was found to be 33.8% and 31.2%, 
respectively. There was a slight increase in seroprevalence of  
both IgG and IgM antibodies (29.4% and 4.4%) among the 
pregnant HIV-positive population over their HIV-negative 
counterparts (28.1% and 3.1%). This difference could be due 
to the immunosuppression consequences in HIV-positive 
individuals which primarily manifests as a drop in their CD4+ 
T-cell counts and function13.
Table 5. Comparison of CD4+ T-cell counts by gestation of HIV-infected pregnant women with serological evidence of toxoplasmosis.
\CD4+ T-cell count (cells/mm3) mean±SD
HIV-seropositive Anti-T. gondii IgG positive (n = 47) HIV-seropositive Anti-T. gondii IgM positive (n = 7)
1st trimester (n 
= 9)
358±28.6 1st trimester (n 
= 1)
399±0
2nd trimester (n 
= 15)
323±24.2 2nd trimester (n 
= 3)
523±41.3
3rd trimester (n 
= 23)
284±18.9
3rd trimester (n 
= 3)
411±38.5
F 37.7689 F 26.8822
P-value <0.0001* P-value 0.0048*
*Significant mean difference determined by one-way ANOVA
Tukey HSD post-hoc test for HIV-seropositive subjects with T. gondii IgG 
1st trimester vs 2nd trimester: Diff. = −35.0000; 95% confidence interval (CI) = −58.1781 to −11.8219; P = 0.0019.
1st trimester vs 3rd trimester: Diff. = −74.0000; 95% CI = −95.6137 to −52.3863; P = 0.0000.
2nd trimester vs 3rd trimester: Diff. = −39.0000; 95% CI = −57.2440 to −20.7560; P = 0.0000.
Tukey HSD post-hoc test for HIV-seropositive subjects with T. gondii IgM
1st trimester vs 2nd trimester: Diff. = 124.0000; 95% CI = −40.2969 to 288.2969; P = 0.11.
1st trimester vs 3rd trimester: Diff. = −115.0000; 95% CI = −279.2969 to 49.2969; P = 0.14.
2nd trimester vs 3rd trimester: Diff. = −239.0000; 95% CI = −355.1755 to −122.8245; P = 0.003.
Table 6. Comparison of CD4+ T-cell counts by gestation of HIV-seronegative pregnant women with serological evidence of toxoplasmosis.
CD4+ T-cell count (cells/mm3) mean±SD
HIV-
seronegative
Anti-T. gondii IgG positive (n = 45) HIV-
seronegative
Anti-T. gondii IgM 
positive (n = 5)
1st trimester 
(n = 6)










582±68.1 3rd trimester (n 
= 3)
598±72.5
F 1.3594 F 2.1255
P-value 0.2679 P-value 0.3199
*Significant mean difference determined by one-way ANOVA.
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The prevalence rates from this study are higher than the 
prevalence of  9.8% and 12.8% among an HIV-positive 
subgroup and HIV-negative pregnant women, respectively, 
reported in South Africa14. The overall seroprevalence in this 
study is in conformity with a previous seroprevalence of  
31.5% recorded in the central city of  Abuja8. The prevalence 
in this study was higher than the 29.9%3 recorded in Zaria 
but lower than others carried out in Lagos and Maiduguri 
where 40.2% and 48.9% were recorded, respectively10,15. The 
variations of  findings from these studies could be due to 
differences in laboratory methods adopted by the studies, 
sample size, HIV and antiretroviral therapy statuses of  study 
participants and endemicity of  toxoplasmosis.
Lagos is a riverine area with a high prevalence of  outdoor 
activities, whereas Maiduguri dwellers have been ravaged by 
national insecurity which grossly affected their standard of  
living and the socioeconomic status of  residents, including 
access to potable water and hygienic meat and vegetables. 
Studies reported within and outside Africa have recorded 
seroprevalence rates among pregnant women of  83.6% in 
Ethiopia16, 92.5% in Ghana17, 48.3% in India18 and 56.6% 
in Brazil19. It is possible that geographical and hot climatic 
conditions in these countries that favour sporulation could 
account for these wide margins in prevalence20,21. The 
climatic condition in our study area may be relatively less 
favourable for the survival of  oocysts compared with studies 
that reported a very high seroprevalence of  toxoplasmosis.
Prevalence rates as low as 10% have been reported in the 
United States and the UK22,23. The lower rates found in 
developed countries are not surprising as these countries 
have higher standards of  living, good potable water and 
proper waste disposal systems that might reduce the risk of  
contracting T. gondii infection.
The highest prevalence of  T. gondii IgG and IgM antibodies 
was observed among women in the age group of  20–39 
years. This was similar in both subgroups. Seroprevalence is 
said to increase with age among both immunocompromised 
and immunocompetent pregnant women8. This may be 
an indicator of  susceptibility to T. gondii infection due to 
occupational hazards such as farming and contact with 
poultry in older populations, compared with younger 
populations who are less involved in these activities24. These 
findings corroborate the reports from Zaria in Nigeria25 and 
Saudi Arabia26.
Toxoplasmosis is a food-borne infection. IgG and IgM 
seropositivity were found to be higher among the urban 
dwellers than their rural counterparts in both the HIV-
positive and HIV-negative pregnant women. This may be 
because urban dwellers are more likely to patronise fast-
food vendors and restaurants with poor sanitary conditions. 
This action may predispose pregnant women, especially the 
‘working class’, to consume poorly prepared vegetables and 
undercooked meat products from unprofessional vendors. A 
similar finding was reported by Nasir et al.15 
There was a statistically significant relationship between 
attaining tertiary level of  education among the HIV-negative 
pregnant women and a higher prevalence of  IgG and IgM 
antibodies.
Although it is generally accepted that highly educated people 
are expected to know about infection prevention measures, 
we observed that this category of  pregnant women might 
have contracted food-borne toxoplasmosis because their 
occupation might have affected their feeding habits, as 
previously explained. To further buttress this, urban residents 
had a higher prevalence of  anti-T. gondii IgG than rural 
residents. However, this opposes other findings in studies 
that showed no significant association between different 
levels of  education26,27.
The highest seroprevalence of  anti-T. gondii IgG antibodies 
for both HIV-positive and HIV-negative pregnant women 
was found in the third trimester (51.1% versus 48.9%) in 
this study. This could be due to the immunosuppressive 
effects of  pregnancy at a late stage (third trimester) 
tending to predispose these women to higher chances of  
contracting T. gondii infection. It has been demonstrated 
that congenital transmission also increases with gestational 
age, with the highest rates in the third trimester11. On the 
other hand, disease severity has been reported to decrease 
with gestational age, with first-trimester infection resulting 
in miscarriage more often28.
The mean CD4+ T-cell counts were found to be significantly 
lower in HIV-positive pregnant women with anti-T. gondii 
IgM antibodies compared with those with IgM seronegative 
results. Similar findings were also reported by Nazari et al.13 
This might be due primarily to the synergistic effects of  HIV 
infection and toxoplasmosis29.
In HIV infection, due to immunosuppression, opportunistic 
infection occurs with T. gondii because of  depletion of  CD4 
Tukey HSD post-hoc test for HIV-seronegative subjects with T. gondii IgG
1st trimester vs 2nd trimester: Diff. = 49.0000; 95% confidence interval (CI) = −32.1196 to 130.1196; P = 0.32.
1st trimester vs 3rd trimester: Diff. = 20.0000; 95% CI = −57.6800 to 97.6800; P = 0.81.
2nd trimester vs 3rd trimester: Diff. = −29.0000; 95% CI = −84.1643 to 26.1643; P = 0.42.
Tukey HSD post-hoc test for HIV-seronegative subjects with T. gondii IgM
1st trimester vs 2nd trimester: Diff. = 115.0000; 95% CI = −488.9721 to 718.9721; P = 0.60.
1st trimester vs 3rd trimester: Diff. = 172.0000; 95% CI = −321.1412 to 665.1412; P = 0.30.
2nd trimester vs 3rd trimester: Diff. = 57.0000; 95% CI = −436.1412 to 550.1412; P = 0.80.
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T cells, impaired production of  IL-12 and interferon gamma 
(IFN-γ) and impaired cytotoxic T-lymphocyte activity29. There 
is decreased in vitro production of  IL-12 and IFN-γ, and 
decreased expression of  CD154 in response to T. gondii29. It 
could be inferred that the women with HIV infection should 
be considered at high risk for developing toxoplasmosis, 
especially when CD4+ T-cell count is very low. CD4+ T-cell 
counts of  less than 100 cells/mm3 have been implicated in 
reactivation of  latent infection which could lead to clinical 
neurologic disease. There are several toxoplasmosis cross-
sectional studies across different subpopulations. However, 
very few have focused on simultaneous investigation of  
toxoplasmosis and its impact on CD4+ T cellular immunity in 
pregnant women living with HIV/AIDS and those who were 
HIV seronegative. In this study, it was shown that primary 
toxoplasmosis in HIV infection significantly altered CD4+ 
T-cell count of  pregnant women. Hence, these findings will 
assist obstetricians and gynaecologists in the early diagnosis 
and management of  T. gondii infection in pregnant women, 
especially HIV-coinfected individuals, to prevent intrauterine 
complications. 
Conclusion
In this study, the seroprevalence of  anti-T. gondii IgG and IgM 
did not differ in the HIV-seropositive or HIV-seronegative 
pregnant population. However, women with primary T. 
gondii and HIV coinfection had lower CD4+ T-cell count than 
those with toxoplasmosis monoinfection. 
Place of  residence and level of  education among HIV-
negative pregnant women have significant association 
with toxoplasmosis. There is a need to educate pregnant 
women about preventive strategies and risk factors that 
could predispose them to T. gondii infection and to prevent 
consequential congenital infections. 
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